Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 0.44 |
| ▸ | CHRNA10 | Q9GZZ6 | 4/20 | 0.44 |
| ▸ | CHRNA9 | Q9UGM1 | 4/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6876940 | 0.95 | TRPA1 (0.42) | CHRNA7CHRNA10CHRNA9RELATRPA1 | |
| SCHEMBL6876942 | 0.95 | TRPA1 (0.42) | CHRNA7CHRNA10CHRNA9RELATRPA1 | |
| SCHEMBL13309559 | 0.94 | CHRNA7 (0.48) | CHRNA7CHRNA10CHRNA9RELATRPA1 | |
| SCHEMBL6883769 | 0.88 | AHR (0.39) | AHR | |
| SCHEMBL6884129 | 0.86 | CHRNA7 (0.44) | CHRNA7CHRNA10CHRNA9RELATRPA1 | |
| SCHEMBL13410112 | 0.83 | ALDH1A1 (0.44) | RELANFE2L2MAPTALDH1A1AHR | |
| SCHEMBL6810747 | 0.83 | NFE2L2 (0.62) | CHRNA7CHRNA10CHRNA9RELATRPA1 | |
| SCHEMBL6810745 | 0.83 | NFE2L2 (0.62) | CHRNA7CHRNA10CHRNA9RELATRPA1 | |
| SCHEMBL5113975 | 0.82 | APP (0.56) | CHRNA7RELATRPA1NFE2L2MAPT | |
| SCHEMBL7607190 | 0.82 | AHR (0.42) | MAPTALDH1A1HPGDAHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055278-A1 | Soluble tetrahedral compounds for use in electroluminescent devices | NATIONAL SCIENCE FOUNDATION | 2003-03-20 | — | — | US | claimed |
| WO-2001083410-A1 | SOLUBLE TETRAHEDRAL COMPOUNDS FOR USE IN ELECTROLUMINESCENT DEVICES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-08 | — | — | WO | claimed |
| US-6824890-B2 | TOPOLOGICAL STRATEGY FOR DESIGNING AMORPHOUS MOLECULAR SOLIDS FOR FORMING THIN FILMS IN OPTOELECTRONIC DEVICES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-11-30 | — | — | US | disclosed |
| US-20030055278-A1 | Soluble tetrahedral compounds for use in electroluminescent devices | NATIONAL SCIENCE FOUNDATION | 2003-03-20 | — | — | US | disclosed |
| WO-2001083410-A1 | SOLUBLE TETRAHEDRAL COMPOUNDS FOR USE IN ELECTROLUMINESCENT DEVICES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055278-A1 | Soluble tetrahedral compounds for use in electroluminescent devices | PAX3, EPCAM, PAXBP1 | CHRNA7 1310/4885CHRNA10 995/4885CHRNA9 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.